Skip to content

Adipotide

An experimental fat-targeting peptide that selectively destroys blood vessels feeding white adipose tissue. Produced dramatic fat loss in primate studies alongside dose-dependent kidney injury, reached a first-in-human Phase 1 trial that enrolled four patients, and has gone nowhere since.

DPreliminaryUse Caution
Last updated 6 citations
TL;DR

Adipotide is an experimental peptide that kills the blood vessels feeding white fat, so the fat cells starve. In obese monkeys it produced genuinely dramatic fat loss — and dose-dependent kidney damage at the same doses. It did reach a first-in-human trial, which enrolled four patients and was terminated without publishing anything. Nothing has been published on it since 2021. It is not a clinical drug, and the kidney risk is a documented finding rather than a theoretical worry.

What is Adipotide?

Adipotide (FTPP) is a synthetic chimeric peptide composed of two functional domains: a cyclic targeting motif (CKGGRAKDC) that selectively binds prohibitin on endothelial cells in white adipose tissue vasculature, fused to D(KLAKLAK)2, a peptidomimetic sequence that disrupts mitochondrial membranes upon internalization. Rather than acting on fat cells directly, adipotide destroys the blood vessels that supply fat tissue, depriving adipocytes of oxygen and nutrients. It produced striking fat loss results in obese primates — a 38.7% fall in body fat percentage across treatment plus recovery — alongside dose-dependent kidney injury. Contrary to a widely repeated claim, adipotide did reach human testing: under the name Prohibitin-TP01 it was given to four patients in a first-in-man Phase 1 trial at MD Anderson (NCT01262664) that ran from 2012 to 2019 and was terminated at the investigator's request without posting results.

What Adipotide Is Investigated For

Adipotide was investigated as a targeted fat-loss agent that destroys the blood vessels supplying white adipose tissue, causing secondary adipocyte death from ischemia. The strongest evidence is a single landmark primate study (Science Translational Medicine, 2011) in obese rhesus macaques: an average 10.6% body weight loss over 28 days of dosing, a 38.7% fall in body fat percentage measured across treatment plus recovery against 14.8% in saline controls, and a 48.5% improvement in the insulinogenic index. Genuinely dramatic preclinical results, and the same study documented dose-dependent renal proximal tubular injury at the doses that produced them, caused by prohibitin expression in kidney tubules. Two things commonly said about adipotide are wrong. First, it was tested in humans: a first-in-man Phase 1 trial (NCT01262664) at MD Anderson, sponsored under the name Prohibitin-TP01 by Ablaris Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals, opened in 2012 with FDA clearance of the investigational new drug application. It enrolled four patients, was terminated at the principal investigator's request, and never posted results. Second, the clean narrative that renal toxicity killed the programme in 2011 is an inference: the trial opened after the toxicity was published and remained open until 2019, and the best-sourced account available says only that development 'has been limited for unknown reasons.' The mechanism itself is also less settled than the page-one story suggests. A formal Comment in Science Translational Medicine argued the weight loss 'may instead reflect a direct effect of adipotide on food consumption,' and the primate paper's own data show food intake fell during dosing and rose after it stopped. Its presence in grey-market research-chemical channels is notable specifically because the kidney toxicity is mechanistically intrinsic to the targeting biology, not a formulation issue that can be engineered away.

Targeted white adipose tissue destruction
Preliminary30%
Rapid fat loss in primate models
Preliminary30%
Insulin resistance improvement
Preliminary30%

History & Discovery

Adipotide was developed in the laboratories of Wadih Arap and Renata Pasqualini at the University of Texas MD Anderson Cancer Center, building on their earlier discovery that prohibitin is selectively expressed on the endothelial cells lining blood vessels of white adipose tissue. The molecule was designed as a chimeric peptidomimetic with two functional halves: a cyclic targeting motif (CKGGRAKDC) identified from in vivo phage-display screens that binds prohibitin, and a synthetic D-amino-acid sequence D(KLAKLAK)2 that disrupts mitochondrial membranes upon receptor-mediated internalization. The premise was direct: rather than reducing food intake or modulating metabolism, eliminate the vasculature feeding white adipose tissue and let the fat cells die from ischemia. The landmark 2011 Science Translational Medicine paper reported that 28 days of subcutaneous adipotide produced 11% body weight loss and a 39% reduction in body fat in obese rhesus macaques, with substantial improvement in insulin resistance. The same paper, however, also documented dose-dependent renal proximal tubule injury — caused by prohibitin expression in kidney tubular cells, an off-target site of the targeting motif. The therapeutic window between fat loss and nephrotoxicity looked narrow enough to make clinical translation difficult, and that reading is the one usually repeated — though as the next paragraph shows, it is not what the record actually documents. What happened next is routinely misreported, including by sources that otherwise take care. Adipotide was licensed and developed as Prohibitin Targeting Peptide 1 — the names adipotide, Prohibitin-TP01 and prohibitin targeting peptide 1 all refer to the same CKGGRAKDC-GG-D(KLAKLAK)2 molecule — by Ablaris Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals. Arrowhead announced FDA clearance to begin a Phase 1 trial and subsequently the dosing of the first patient. That trial, NCT01262664, opened at MD Anderson in May 2012 in men with metastatic prostate cancer and obesity, giving a daily subcutaneous injection for 28 days across planned dose levels, with eligibility limits on serum creatinine and proteinuria that read as direct management of the known renal liability. It enrolled four participants, was recorded as completed in January 2019, and is listed as terminated at the principal investigator's request. No results were posted. So the frequently repeated claim that adipotide was never given to a human is false — though what human exposure produced was never published. Why the programme stopped has never been stated publicly. The tidy story that primate nephrotoxicity killed it does not fit the dates, since the Phase 1 opened a year after that toxicity was published and stayed open for seven years. A 2025 review of adipose-tissue-targeting drug development records the programme as Phase 1, discontinued in January 2019, and says only that 'further development of adipotide has been limited for unknown reasons.' Academic interest in the underlying chemistry has continued: a mixed-chirality prohibitin peptide from Chan and colleagues (J Am Chem Soc, July 2025) reported improved stability and weight reduction in a high-fat-diet mouse model, with the authors describing a general favourable preclinical safety profile. Note that its most potent compound works by inducing mitochondrial uncoupling rather than by the targeted vascular apoptosis that defined adipotide, so it is a successor scaffold rather than a continuation of the same mechanism, and whether it avoids the renal tubular liability is not established at the abstract level. Against that, no paper has named adipotide itself since 2021 — roughly a dozen papers mention it in all of PubMed — so the molecule, as distinct from the chemistry around it, is dormant.

How It Works

Adipotide works like a guided missile for fat tissue. One part of the peptide finds and locks onto blood vessels that specifically feed fat deposits. The other part punches holes in those blood vessel cells, destroying them. Without blood supply, the fat tissue starves and shrinks. The problem is that the "missile" can also hit kidney blood vessels, causing damage.

Adipotide is a chimeric peptide with two functional domains. The N-terminal cyclic motif CKGGRAKDC binds to prohibitin, a receptor selectively expressed on the surface of endothelial cells in white adipose tissue vasculature. Upon receptor-mediated internalization, the C-terminal D(KLAKLAK)2 domain — a synthetic sequence composed entirely of D-amino acids for protease resistance — disrupts mitochondrial membranes, triggering apoptosis in the target endothelial cells. The resulting vascular destruction deprives white adipose tissue of blood supply, leading to adipocyte death and resorption. In obese rhesus macaques, this mechanism produced a 38.7% decrease in body fat percentage measured from baseline to the end of the 28-day recovery period (DEXA-confirmed; saline controls fell 14.8% on the same measure) and a 36.2% decrease in insulin AUC, at 0.43 mg/kg/day for 28 days. The kidney toxicity results from prohibitin expression in renal proximal tubular cells, where adipotide causes off-target tubular degeneration and single-cell necrosis.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

Essentially none, but not zero. A first-in-man Phase 1 dose-escalation trial (NCT01262664) at MD Anderson Cancer Center gave adipotide — registered as Prohibitin Targeting Peptide 1 — by daily subcutaneous injection for 28 days to men with metastatic prostate cancer and obesity. It opened in May 2012 under an FDA-cleared IND, enrolled 4 of its planned participants, was recorded complete in January 2019, and is listed as terminated at the principal investigator's request. No results were ever posted, so the trial contributes human exposure but no usable human safety or efficacy data. No other human trial has ever been registered.

Animal / Preclinical

Strong within primates, with important qualifications. The efficacy work was done in rhesus macaques (n = 39) with a small baboon cohort (n = 2); a separate cohort of 52 cynomolgus macaques was a safety study for the whole class of targeted D(KLAKLAK)2 drugs rather than an adipotide efficacy experiment, so the three cohorts should not be added together as evidence of effect. Findings: dose-dependent weight loss (an initial two-animal escalation cohort reached 20.4% over nine weeks; the fixed-dose study averaged 10.6% over 28 days), a 38.7% decrease in body fat percentage across treatment plus recovery versus 14.8% in saline controls, and a 48.5% reduction in the insulinogenic index. MRI and DEXA confirmed white adipose tissue volume decreases. Dose-dependent renal tubular injury occurred at therapeutic doses; most serum and urine changes reversed within 28 days of stopping, but one treated monkey per study retained slightly elevated creatinine and urinary glucose, and minimal tubular degeneration was still visible at necropsy in three monkeys after the full recovery period.

Mechanistic Rationale

Strong. The vascular targeting mechanism is well-characterized: prohibitin binding, endothelial cell internalization, mitochondrial membrane disruption, and subsequent adipose tissue ischemia. The off-target kidney toxicity is also mechanistically understood (prohibitin expression in renal tubules). Published in Science Translational Medicine.

Research Gaps & Open Questions

What the current literature has not yet settled about Adipotide:

  • 01Whether a safer dosing regimen (lower dose, intermittent dosing, alternate route) could preserve fat-loss efficacy while avoiding nephrotoxicity was never published. A Phase 1 dose-escalation designed to answer exactly this question enrolled four patients and reported nothing, so the dose-response relationship in humans remains entirely uncharacterised.
  • 02How much of the fat loss is vascular pruning and how much is reduced food intake. A published Comment in Science Translational Medicine argued the monkey weight loss may reflect a direct effect on food consumption, and the primate data show intake falling during dosing and rising afterwards. The two mechanisms were never disentangled, which matters because a drug that works largely by suppressing appetite would carry the renal risk without the mechanistic advantage that justifies it.
  • 03Whether the fat loss observed in primates would be durable in humans is unknown — no human exposure has ever occurred.
  • 04Modified targeting motifs that retain prohibitin binding selectivity for adipose vasculature while sparing renal tubular endothelium would address the central liability of the original chimera. A mixed-chirality prohibitin peptide, D-(RLARLAR)2, was reported in J Am Chem Soc July 2025 (PMID 40591817) with improved stability and in vivo obesity effects — the first genuinely new prohibitin-targeting successor program since 2011, though whether it also addresses the renal tubular off-target liability of the original adipotide chimera is not yet established.
  • 05Long-term effects on adipose tissue regeneration and metabolic recovery after vasculature destruction are not well characterized.
  • 06Effects on brown adipose tissue (which does not strongly express the same prohibitin pattern) versus white adipose tissue have not been formally distinguished in vivo.
  • 07Real-world adverse event data from grey-market human use are absent from the literature entirely. A search of PubMed for adipotide alongside acute kidney injury, nephrotoxicity or case reports returns nothing — there are no published case reports of harm from grey-market use, which reflects the absence of surveillance rather than evidence of safety. Combined with the Phase 1 trial posting no results, there is no human safety dataset for this molecule from any source.

Forms & Administration

Adipotide was administered via daily subcutaneous injection in primate studies at 0.43 mg/kg. It is not approved for human use and is not available through legitimate medical channels. Due to documented kidney toxicity, this peptide should not be self-administered under any circumstances.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

There is no human dose. The published preclinical regimen in obese rhesus macaques was 0.43 mg/kg/day subcutaneously for 28 days. Material sold under the adipotide name in research-chemical channels typically carries vague dosing recommendations that have no clinical evidence base whatsoever — these dosing claims should be regarded as inventions, not protocols.

Frequency

Daily subcutaneous injection in the published primate studies. Any human dosing claim is fabricated.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

The published primate protocol was 28 days, after which the dose-dependent renal injury was the limiting factor. Most serum and urine abnormalities resolved within 28 days of stopping, though residual creatinine and glucose elevations and minimal tubular degeneration persisted in a minority of animals. There is no concept of a 'safe cycle' in humans: the one Phase 1 trial that dosed humans on this 28-day schedule enrolled four patients and published nothing, so no safe or unsafe human dose has ever been established.

Protocol Notes

Adipotide is not a clinical drug. It exists in the research-chemical and grey-market peptide space because the primate fat-loss data is striking, but the same primate data documented kidney damage that derailed clinical development. Anyone considering adipotide should understand that the renal toxicity is not theoretical or speculative — it was directly observed in non-human primate studies at the doses that produced the fat loss. The mechanism (prohibitin expression in renal proximal tubule cells, leading to tubular degeneration and necrosis) is intrinsic to the molecule's design, not a fixable formulation issue. There is no antidote, no monitoring protocol that would catch damage before it occurred, and no safer dosing regimen has been characterized.

Adipotide is not approved by any regulatory authority for human use, has never been tested in human clinical trials, and demonstrated dose-dependent renal toxicity in primate studies at therapeutic doses. Self-administration is dangerous and is strongly discouraged.

Timeline of Effects

Onset

In the rhesus macaque study, fat loss became measurable within the 28-day dosing window via DEXA imaging. Kidney injury markers (elevated serum creatinine, glucosuria, proteinuria) emerged in the same window, dose-dependent and concurrent with the therapeutic effect.

Peak Effect

The published primate data documented up to 11% body weight loss and 38.7% body fat reduction over 28 days at 0.43 mg/kg/day. Whether longer dosing would produce greater fat loss before causing irreversible kidney injury was not tested because development was discontinued.

After Discontinuation

In primates, most renal abnormalities reversed within 28 days of stopping adipotide, with residual creatinine and urinary glucose elevations in one treated monkey per study and minimal tubular degeneration still present at necropsy in three. The fat and weight findings diverge during recovery and are often reported as if they did not: body weight, BMI and abdominal circumference 'began to slowly reverse' across the 4-week recovery period, while total body fat percentage continued to fall. Food intake also rose again after dosing stopped. Longer-term durability was never assessed, and the underlying mechanism would predict gradual revascularization over months. No human discontinuation data exist — the only human trial never reported outcomes.

Monitoring & Measurement

Bloodwork & Labs

  • •Serum creatinine and eGFR — the single most important measure, given dose-dependent proximal tubular injury at the doses that produced fat loss in primates
  • •Urinalysis with urine protein and urine glucose — glucosuria and proteinuria were the earliest and most consistent signals in the monkey studies, appearing alongside the therapeutic effect rather than after it
  • •Urine microscopy for renal tubular epithelial cells — increased transitional and renal epithelial cells were a documented finding
  • •Serum electrolytes including potassium — mild-to-moderate time- and dose-dependent decreases were reported
  • •Fasting glucose and insulin — the primate work showed substantial insulin-sensitivity changes independent of weight

Functional & Performance Tests

  • •DEXA scan for body composition, since the claimed effect is specifically on white adipose tissue rather than scale weight
  • •Body weight, BMI and abdominal circumference on a fixed schedule — the three measures tracked in the primate studies

When to Test

Baseline, then weekly during any exposure, and again 4 weeks after stopping.

Interpretation & Notes

This monitoring list exists to describe what the primate toxicology would require, not to make self-administration sound manageable. It is not: in the monkey studies the renal injury was concurrent with the fat loss rather than following it, meaning there is no window in which you get the benefit and then watch for harm. Weekly creatinine and urinalysis is the minimum the published toxicology implies, and even that would likely detect tubular injury only once it was established — the monkeys were necropsied to characterise it, which is not an option here. Note also that most but not all abnormalities reversed within 28 days of stopping in primates, so a normal result after cessation does not guarantee full recovery. Serum creatinine, eGFR, electrolytes and urinalysis are inexpensive and available through any standard lab; DEXA is widely available. Anyone who has already taken this compound should get renal function checked regardless of how they feel, because tubular injury is typically asymptomatic until it is advanced.

Common Questions

How is adipotide different from GLP-1 drugs like semaglutide?

The primary mechanism is completely different. GLP-1 drugs reduce appetite and slow gastric emptying. Adipotide destroys the blood supply to fat tissue, causing fat cells to die from lack of nutrients. But the common claim that adipotide has no effect on appetite is not accurate. The primate paper itself reported that food consumption 'decreased with continued dosing and appeared to increase after cessation of drug administration' in treated animals, and one of the foundational rodent papers is titled 'Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight.' A formal Comment published in Science Translational Medicine argued that the monkey weight loss 'may instead reflect a direct effect of adipotide on food consumption' rather than vascular pruning. How much of the effect is vascular and how much is reduced eating was never resolved.

Was adipotide ever tested in humans?

Yes — this is the most commonly repeated error about adipotide. A first-in-man Phase 1 trial, NCT01262664, ran at MD Anderson Cancer Center in men with metastatic prostate cancer and obesity, using the name Prohibitin Targeting Peptide 1 (Prohibitin-TP01). The protocol gave a daily subcutaneous injection for 28 days, the same regimen used in monkeys, across planned dose levels. FDA cleared the investigational new drug application and the sponsor, Ablaris Therapeutics — a majority-owned subsidiary of Arrowhead Pharmaceuticals — announced dosing of the first patient. The trial started in May 2012, was recorded as completed in January 2019, and is listed as terminated with the reason given as the principal investigator's request. Only four participants were enrolled and no results were ever posted. So human exposure happened, but it produced no published safety or efficacy data.

Why did adipotide development stop?

Honestly, nobody has said. The usual explanation — that the primate kidney toxicity killed it — is an inference rather than a sourced fact, and the timeline does not fit neatly: the toxicity was published in 2011 and the Phase 1 trial began in 2012 and remained open until 2019. What is documented is that dose-dependent renal injury was real (elevated serum creatinine, glucosuria, proteinuria, tubular degeneration and single-cell necrosis), that the Phase 1 enrolled only four of its planned participants before terminating at the investigator's request, and that a 2025 review of adipose-targeting drugs states simply that 'further development of adipotide has been limited for unknown reasons.' No paper has named adipotide since 2021.

Is adipotide available?

Adipotide is not FDA-approved, is not in any active clinical trial, and is not available through legitimate medical channels. It circulates in the gray-market research peptide space, but its kidney toxicity profile makes unsupervised use particularly dangerous — and because the only human trial never reported results, there is no human safety dataset of any kind to reason from.

How much fat loss did adipotide actually produce in primates?

In the 2011 Science Translational Medicine study of obese rhesus macaques, 28 days of subcutaneous adipotide at 0.43 mg/kg/day produced an average 10.6% body weight loss, with individual animals ranging from −7.4% to −14.7%. Insulin sensitivity improved substantially (48.5% reduction in the insulinogenic index, against a 33.8% increase in controls). The widely quoted 38.7% body fat figure needs two caveats that are almost always dropped: it is measured from the start of the study to the end of the 28-day recovery period — 56 days, not 28 — and saline control animals fell 14.8% on the same measure over the same window, so the placebo-corrected difference is roughly 24 percentage points rather than 38.7. The separate 20.4% figure sometimes cited comes from an initial dose-escalation cohort of just two monkeys dosed for nine weeks. The results were genuinely striking; the same study documented dose-dependent renal proximal tubular injury at the doses that produced them.

Why does adipotide damage the kidneys if it is supposed to target fat tissue?

The targeting motif (CKGGRAKDC) binds prohibitin, a receptor that is selectively — but not exclusively — expressed on endothelial cells in white adipose tissue vasculature. Prohibitin is also expressed on renal proximal tubular cells, which is the off-target site. When adipotide reaches the kidneys, the same membrane-disrupting payload that destroys fat-feeding blood vessels causes tubular degeneration and single-cell necrosis. The toxicity is intrinsic to the targeting biology, not a formulation problem.

Who Adipotide Is NOT For

Contraindications
  • •Existing kidney disease or impaired renal function — the documented dose-dependent nephrotoxicity makes adipotide affirmatively dangerous in this population, where the renal reserve to absorb tubular injury is already reduced.
  • •Diabetes with established or developing nephropathy — same renal-reserve concern applies.
  • •Pregnancy and breastfeeding — no human safety data, and the mechanism (vasculature destruction) is the kind of pharmacology incompatible with fetal development.
  • •Pediatric use — entirely contraindicated; no pediatric data and no plausible justification for risk in a developing population.
  • •Concurrent use of other nephrotoxic agents (NSAIDs at therapeutic doses, aminoglycoside antibiotics, contrast agents, certain chemotherapy) — additive renal injury risk.
  • •Hypovolemia or dehydration — increases vulnerability to renal tubular injury.
  • •Effectively, adipotide should be regarded as contraindicated in all human populations until and unless a regulated clinical trial establishes a safe and effective dosing window — which has not happened in over a decade since the primate data were published.

Drug & Supplement Interactions

Documented drug-interaction data for adipotide in humans are nonexistent. Four patients did receive it in a regulated Phase 1 trial, but that study posted no results, so it contributes nothing to the interaction picture. The most clinically relevant theoretical interaction is with other nephrotoxic agents — NSAIDs (especially at higher doses), aminoglycoside antibiotics, IV contrast agents, certain chemotherapy regimens, and other proximal-tubule-active drugs — which would compound the dose-dependent renal injury observed in primates. Diuretic use during dehydration could similarly increase tubular vulnerability. The vascular-targeting mechanism could in principle interact with anti-angiogenic oncology therapies (bevacizumab, VEGF tyrosine kinase inhibitors) in unpredictable ways, though the specific tissue-targeting profile (white adipose tissue plus off-target renal tubular endothelium) does not overlap closely with tumor angiogenesis. Beyond these theoretical concerns, the absence of human pharmacology data means any drug-interaction discussion is fundamentally speculative.

Safety Profile

Safety Information

Common Side Effects

Dose-dependent kidney toxicity (elevated creatinine, tubular degeneration)Glucosuria and proteinuriaIncreased epithelial cells in urine

Cautions

  • • Clinical development was discontinued due to kidney toxicity
  • • Narrow therapeutic window between effective and toxic doses
  • • Not FDA-approved and not in clinical trials
  • • Gray market sources have unknown purity and composition
  • • Should NOT be self-administered — kidney damage risk is real and documented

What We Don't Know

No human clinical data exists. The kidney toxicity observed in primates was reversible within 28 days, but long-term effects of repeated exposure are unknown. Whether a safer dosing regimen could preserve efficacy while avoiding renal damage has not been explored.

Myths & Misconceptions

Myth

Adipotide is a clinical drug being studied for obesity.

Reality

Adipotide is not currently in development anywhere: no active trial, no sponsor, and no paper naming it since 2021. It is not FDA-approved and exists today only in research-chemical channels. It is, however, further along than 'preclinical only' suggests — it held an FDA-cleared IND and a four-patient Phase 1 trial ran from 2012 to 2019 before terminating without results. Past Phase 1 exposure with nothing published is not the same as an ongoing clinical programme.

Myth

Adipotide was never given to a human.

Reality

It was. NCT01262664, a first-in-man Phase 1 at MD Anderson Cancer Center, enrolled four men with metastatic prostate cancer and obesity and gave daily subcutaneous injections for 28 days under the compound's development name, Prohibitin Targeting Peptide 1. The trial registration states plainly that this was the first study using the compound in humans. It was terminated at the investigator's request and no results were ever posted — which is why the claim persists, and why human exposure still tells us essentially nothing about human safety.

Myth

The kidney toxicity in primates was reversible, so it is fine to use adipotide as long as you stop in time.

Reality

The primate renal injury was reversible within 28 days in controlled laboratory conditions with continuous monitoring. Real-world human use lacks the monitoring infrastructure that would catch tubular injury before it became significant, and reversibility cannot be assumed for higher doses, longer exposures, or patients with reduced renal reserve. The mechanism (prohibitin expression in renal tubule cells) is intrinsic and not reformulatable.

Myth

Adipotide selectively kills only fat cells.

Reality

Adipotide does not target fat cells (adipocytes) at all. It targets the endothelial cells lining the blood vessels that feed white adipose tissue. The fat cells die secondarily from ischemia. The same prohibitin receptor that the targeting motif recognizes is also expressed on renal tubular cells, which is the source of the off-target toxicity. The selectivity is real but imperfect, and the imperfection is what derailed clinical development.

Myth

Because adipotide produces real fat loss, the risks are worth it for cosmetic or athletic goals.

Reality

The risk in question is acute kidney injury, including tubular degeneration and necrosis, in healthy people taking an unstudied molecule under no medical supervision. There is no aesthetic or athletic outcome for which this risk is reasonable, and there is no monitoring protocol that reliably catches damage before it occurs. The published data establish what adipotide does to kidneys at doses that produce fat loss.

Published Research

6 studies

Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT).

ReviewPMID: 40760703

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity.

J Am Chem Soc July 2025 successor to the adipotide scaffold — a mixed-chirality prohibitin-targeting peptide, D-(RLARLAR)2, with improved stability and in vivo obesity effects. The first genuinely new prohibitin-targeting-peptide obesity program published since the 2011 rhesus macaque adipotide paper, directly relevant to the file's own research gap on whether modified targeting motifs preserving prohibitin selectivity have been published as a successor program.

PreclinicalPMID: 40591817

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.

PreclinicalPMID: 22733798

Comment on "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

A formal Comment published in Science Translational Medicine challenging the central mechanistic claim of the primate study — arguing the weight loss 'may instead reflect a direct effect of adipotide on food consumption' rather than destruction of adipose vasculature. The vascular-versus-appetite question it raises was never resolved, and the primate paper's own feeding data are consistent with it.

CommentaryPMID: 22539771

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys.

Preclinical

Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight.

Preclinical

Quick Facts

Class
Proapoptotic Peptide
Tier
D
Evidence
Preliminary
Safety
Use Caution
Updated
Oct 2026
Citations
6PubMed

Also known as

FTPPFat-Targeted Proapoptotic PeptideProhibitin-Targeting Peptide

Tags

Fat LossExperimentalProapoptoticVascular TargetingDiscontinued

Related Goals

Weight LossBody Composition

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.